AbbVie Analyst Ratings
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $221
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $231
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
Deutsche Bank Adjusts AbbVie Price Target to $180 From $175, Maintains Hold Rating
AbbVie Analyst Ratings
Argus Research Upgrades AbbVie(ABBV.US) to Buy Rating
Goldman Sachs Raises Price Target on AbbVie to $210 From $208
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie Price Target Raised to $200.00/Share From $195.00 by UBS
AbbVie Is Maintained at Neutral by UBS
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $205 to $240
AbbVie Analyst Ratings
Morgan Stanley Raises Price Target on AbbVie to $231 From $218, Keeps Overweight Rating
Evercore ISI Adjusts Price Target on AbbVie to $204 From $192
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie Is Maintained at Buy by Citigroup
No Data
No Data